25 XP   0   0   10

Leap Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Leap Therapeutics Inc together

PenkeI guess you are interested in Leap Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Leap Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Leap Therapeutics Inc

I send you an email if I find something interesting about Leap Therapeutics Inc.

Quick analysis of Leap Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Leap Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$2.23
Expected worth in 1 year
$2.16
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.07
Return On Investment
-2.2%

For what price can you sell your share?

Current Price per Share
$3.21
Expected price per share
$2.125 - $4.39
How sure are you?
50%

1. Valuation of Leap Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$3.21

Intrinsic Value Per Share

$-19.49 - $-13.75

Total Value Per Share

$-17.27 - $-11.52

2. Growth of Leap Therapeutics Inc (5 min.)




Is Leap Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$60.1m$77.7m-$16.5m-27.1%

How much money is Leap Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$20.1m-$13.9m-$6.1m-30.6%
Net Profit Margin-491.5%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Leap Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#451 / 1011

Most Revenue
#609 / 1011

Most Profit
#694 / 1011

Most Efficient
#739 / 1011

What can you expect buying and holding a share of Leap Therapeutics Inc? (5 min.)

Welcome investor! Leap Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Leap Therapeutics Inc.

What can you expect buying and holding a share of Leap Therapeutics Inc?

First you should know what it really means to hold a share of Leap Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Leap Therapeutics Inc is $3.21. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Leap Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Leap Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.23. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Leap Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.46-14.4%-0.78-24.4%-0.53-16.6%-0.48-15.0%-0.42-13.1%
Usd Book Value Change Per Share-0.44-13.7%-0.02-0.6%-0.48-14.9%0.092.9%0.041.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.000.0%
Usd Total Gains Per Share-0.44-13.7%-0.02-0.6%-0.48-14.9%0.103.0%0.041.2%
Usd Price Per Share4.15-2.25-1.06-1.89-2.32-
Price to Earnings Ratio-2.24--1.12--0.53--1.22--1.36-
Price-to-Total Gains Ratio-9.43--2.63--2.37-4.84--11.31-
Price to Book Ratio1.86-0.91-0.33-0.65-3.17-
Price-to-Total Gains Ratio-9.43--2.63--2.37-4.84--11.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.21
Number of shares311
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.09
Usd Total Gains Per Share-0.020.10
Gains per Quarter (311 shares)-5.5230.07
Gains per Year (311 shares)-22.06120.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-22-324116110
20-44-548233230
30-66-7612349350
40-88-9816465470
50-110-12020582590
60-132-14224698710
70-154-16428814830
80-177-18632931950
90-199-2083610471070
100-221-2304011631190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.042.00.04.5%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.014.01.025.0%10.028.02.025.0%12.028.04.027.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%5.00.015.025.0%5.00.035.012.5%5.00.039.011.4%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%11.028.01.027.5%13.028.03.029.5%

Fundamentals of Leap Therapeutics Inc

About Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 13:40:09.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Leap Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Leap Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -1,966.1% means that $-19.66 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Leap Therapeutics Inc:

  • The MRQ is -1,966.1%. The company is making a huge loss. -2
  • The TTM is -491.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,966.1%TTM-491.5%-1,474.6%
TTM-491.5%YOY--491.5%
TTM-491.5%5Y-1,006.3%+514.8%
5Y-1,006.3%10Y-503.2%-503.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,966.1%-196.1%-1,770.0%
TTM-491.5%-211.9%-279.6%
YOY--277.7%+277.7%
5Y-1,006.3%-432.9%-573.4%
10Y-503.2%-599.3%+96.1%
1.1.2. Return on Assets

Shows how efficient Leap Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • -17.1% Return on Assets means that Leap Therapeutics Inc generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Leap Therapeutics Inc:

  • The MRQ is -17.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.1%TTM-21.5%+4.4%
TTM-21.5%YOY-16.2%-5.3%
TTM-21.5%5Y-23.5%+2.0%
5Y-23.5%10Y-30.1%+6.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.1%-13.3%-3.8%
TTM-21.5%-12.7%-8.8%
YOY-16.2%-11.8%-4.4%
5Y-23.5%-14.0%-9.5%
10Y-30.1%-15.9%-14.2%
1.1.3. Return on Equity

Shows how efficient Leap Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • -20.7% Return on Equity means Leap Therapeutics Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Leap Therapeutics Inc:

  • The MRQ is -20.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -50.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.7%TTM-50.1%+29.4%
TTM-50.1%YOY-18.7%-31.4%
TTM-50.1%5Y-31.6%-18.5%
5Y-31.6%10Y-31.9%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.7%-16.9%-3.8%
TTM-50.1%-16.0%-34.1%
YOY-18.7%-15.1%-3.6%
5Y-31.6%-19.7%-11.9%
10Y-31.9%-20.5%-11.4%

1.2. Operating Efficiency of Leap Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Leap Therapeutics Inc is operating .

  • Measures how much profit Leap Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -2,337.5% means the company generated $-23.38  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Leap Therapeutics Inc:

  • The MRQ is -2,337.5%. The company is operating very inefficient. -2
  • The TTM is -584.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,337.5%TTM-584.4%-1,753.2%
TTM-584.4%YOY--584.4%
TTM-584.4%5Y-1,031.3%+446.9%
5Y-1,031.3%10Y-515.6%-515.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,337.5%-290.9%-2,046.6%
TTM-584.4%-224.4%-360.0%
YOY--288.3%+288.3%
5Y-1,031.3%-479.5%-551.8%
10Y-515.6%-625.2%+109.6%
1.2.2. Operating Ratio

Measures how efficient Leap Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 23.38 means that the operating costs are $23.38 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Leap Therapeutics Inc:

  • The MRQ is 23.375. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.844. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ23.375TTM5.844+17.532
TTM5.844YOY-+5.844
TTM5.8445Y10.753-4.909
5Y10.75310Y5.377+5.377
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.3753.110+20.265
TTM5.8443.266+2.578
YOY-3.783-3.783
5Y10.7535.657+5.096
10Y5.3777.783-2.406

1.3. Liquidity of Leap Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Leap Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.64 means the company has $5.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Leap Therapeutics Inc:

  • The MRQ is 5.645. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.797. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.645TTM7.797-2.152
TTM7.797YOY9.010-1.213
TTM7.7975Y6.758+1.039
5Y6.75810Y8.345-1.587
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6453.905+1.740
TTM7.7974.212+3.585
YOY9.0105.337+3.673
5Y6.7586.062+0.696
10Y8.3456.401+1.944
1.3.2. Quick Ratio

Measures if Leap Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.63 means the company can pay off $5.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Leap Therapeutics Inc:

  • The MRQ is 5.630. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.764. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.630TTM7.764-2.134
TTM7.764YOY8.968-1.203
TTM7.7645Y6.724+1.040
5Y6.72410Y9.202-2.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6303.572+2.058
TTM7.7644.001+3.763
YOY8.9685.364+3.604
5Y6.7246.009+0.715
10Y9.2026.287+2.915

1.4. Solvency of Leap Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Leap Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Leap Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Leap Therapeutics Inc assets are financed with 17.4% credit (debt) and the remaining percentage (100% - 17.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Leap Therapeutics Inc:

  • The MRQ is 0.174. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.174TTM0.291-0.117
TTM0.291YOY0.124+0.167
TTM0.2915Y0.289+0.002
5Y0.28910Y0.533-0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1740.336-0.162
TTM0.2910.334-0.043
YOY0.1240.271-0.147
5Y0.2890.366-0.077
10Y0.5330.389+0.144
1.4.2. Debt to Equity Ratio

Measures if Leap Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.1% means that company has $0.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Leap Therapeutics Inc:

  • The MRQ is 0.211. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.816. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.211TTM0.816-0.606
TTM0.816YOY0.143+0.673
TTM0.8165Y0.450+0.367
5Y0.45010Y0.524-0.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2110.382-0.171
TTM0.8160.397+0.419
YOY0.1430.341-0.198
5Y0.4500.432+0.018
10Y0.5240.465+0.059

2. Market Valuation of Leap Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Leap Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Leap Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.24 means the investor is paying $-2.24 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Leap Therapeutics Inc:

  • The EOD is -1.737. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.244. Based on the earnings, the company is expensive. -2
  • The TTM is -1.118. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.737MRQ-2.244+0.506
MRQ-2.244TTM-1.118-1.126
TTM-1.118YOY-0.531-0.587
TTM-1.1185Y-1.219+0.101
5Y-1.21910Y-1.363+0.144
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.737-2.262+0.525
MRQ-2.244-2.599+0.355
TTM-1.118-2.674+1.556
YOY-0.531-4.133+3.602
5Y-1.219-6.258+5.039
10Y-1.363-6.171+4.808
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Leap Therapeutics Inc:

  • The EOD is -2.086. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.694. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.430. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.086MRQ-2.694+0.608
MRQ-2.694TTM-1.430-1.264
TTM-1.430YOY-0.563-0.867
TTM-1.4305Y-1.487+0.057
5Y-1.48710Y-2.359+0.872
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.086-2.913+0.827
MRQ-2.694-3.275+0.581
TTM-1.430-3.508+2.078
YOY-0.563-5.620+5.057
5Y-1.487-8.306+6.819
10Y-2.359-8.854+6.495
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Leap Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.86 means the investor is paying $1.86 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Leap Therapeutics Inc:

  • The EOD is 1.440. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.860. Based on the equity, the company is underpriced. +1
  • The TTM is 0.909. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.440MRQ1.860-0.420
MRQ1.860TTM0.909+0.951
TTM0.909YOY0.331+0.578
TTM0.9095Y0.651+0.259
5Y0.65110Y3.168-2.518
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4401.858-0.418
MRQ1.8602.090-0.230
TTM0.9092.091-1.182
YOY0.3312.866-2.535
5Y0.6513.488-2.837
10Y3.1683.836-0.668
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Leap Therapeutics Inc.

3.1. Institutions holding Leap Therapeutics Inc

Institutions are holding 30.372% of the shares of Leap Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP4.5850.0553117217500
2023-12-31Adage Capital Partners Gp LLC3.68830.008194291800
2023-12-31Rock Springs Capital Management LP3.25810.085832937-241580-22.4827
2023-12-31Samsara BioCapital, LLC2.6180.43166693036710011.1424
2023-09-30Citadel Advisors Llc2.51990.0002644219559615661.4522
2023-12-31683 Capital Management LLC1.76020.1528450000-40000-8.1633
2023-12-31Vanguard Group Inc1.60304098047509122.4344
2023-12-31Longwood Capital Partners LLC1.38530.826335416600
2023-12-31Key Client Fiduciary Advisors, LLC0.83950.516214610-12663-5.5717
2023-12-31Geode Capital Management, LLC0.79780.00012039606028341.9573
2023-12-31UBS O'Connor LLC0.56170.0428143589-75845-34.5639
2023-12-31Susquehanna International Group, LLP0.49890.00011275411275410
2023-12-31T. Rowe Price Associates, Inc.0.46630.0001119200-325000-73.1652
2023-12-31BlackRock Inc0.372209515650373112.4824
2023-12-31State Street Corporation0.247306321335500128.0987
2023-12-31Acadian Asset Management LLC0.24580.00162850628500
2023-12-31Perceptive Advisors LLC0.17590.00424497100
2023-12-31Northern Trust Corp0.17430445581641258.3102
2023-12-31T. Rowe Price Investment Management,Inc.0.13850.00013540000
2023-12-31SIMPLEX TRADING, LLC0.09330.00012384418918384.0438
Total 26.02932.12386654414+378595+5.7%

3.2. Funds holding Leap Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.46090.000162998710205219.3304
2024-02-29Simplify Health Care ETF1.1850.80113033522959403992.7145
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.77250.00051977643244719.6271
2024-02-29Fidelity Extended Market Index0.42290.0008108260-525-0.4826
2023-12-31BIT Global Leaders I - I0.31640.6853810002700050
2023-12-31T. Rowe Price New Horizons0.24410.00096250000
2023-12-31US Small-Cap Growth II Equity Comp0.24410.000962500625000
2023-12-31Janus Henderson Global Life Sciences0.18550.0034750000
2023-12-31T. Rowe Price Health Sciences0.16950.001143400-288613-86.9282
2023-12-31Janus Selection Global Life Science AUSD0.13280.002934000-255560-88.258
2024-02-29Fidelity Total Market Index0.11220.00012871600
2024-02-29Fidelity Series Total Market Index0.10720.000127450-1388-4.8131
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.10240.00172620720284342.4616
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.08220.00172104816300343.3024
2023-12-31T. Rowe Price US Small-Cap Core Equity0.06950.00071780000
2023-12-31T. Rowe Price Small-Cap Stock0.06950.00071780000
2023-12-31Northern Trust Extended Eq Market Idx0.06920.001317719-3872-17.9334
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06920.001317719-3872-17.9334
2024-02-29Fidelity Nasdaq Composite Index0.06060.00031551900
2023-09-30BlackRock Extended Mkt Composite0.05740.00011468200
Total 6.93311.50461774923+2693+0.2%

3.3. Insider Transactions

Insiders are holding 2.958% of the shares of Leap Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2020-06-22Perceptive Advisors LlcBUY17500002
2019-02-05Christopher MirabelliBUY5714281.75
2017-11-14Augustine LawlorBUY10577696.09

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Leap Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.440-0.018-96%-0.479+9%0.094-570%0.037-1276%
Book Value Per Share--2.2292.322-4%3.035-27%2.037+9%1.402+59%
Current Ratio--5.6457.797-28%9.010-37%6.758-16%8.345-32%
Debt To Asset Ratio--0.1740.291-40%0.124+41%0.289-40%0.533-67%
Debt To Equity Ratio--0.2110.816-74%0.143+47%0.450-53%0.524-60%
Dividend Per Share----0%-0%0.003-100%0.002-100%
Eps---0.462-0.782+69%-0.533+15%-0.481+4%-0.421-9%
Free Cash Flow Per Share---0.385-0.417+8%-0.479+25%-0.352-9%-0.284-26%
Free Cash Flow To Equity Per Share--3.3480.516+549%-0.483+114%0.030+10895%0.077+4268%
Gross Profit Margin--1.0091.002+1%1.000+1%1.000+1%1.000+1%
Intrinsic Value_10Y_max---13.753--------
Intrinsic Value_10Y_min---19.495--------
Intrinsic Value_1Y_max---1.173--------
Intrinsic Value_1Y_min---1.714--------
Intrinsic Value_3Y_max---3.681--------
Intrinsic Value_3Y_min---5.388--------
Intrinsic Value_5Y_max---6.378--------
Intrinsic Value_5Y_min---9.295--------
Market Cap82176321.000-36%111861869.39059484131.888+88%27072105.750+313%48850570.728+129%59497422.364+88%
Net Profit Margin---19.661-4.915-75%--100%-10.063-49%-5.032-74%
Operating Margin---23.375-5.844-75%--100%-10.313-56%-5.156-78%
Operating Ratio--23.3755.844+300%-+100%10.753+117%5.377+335%
Pb Ratio1.440-29%1.8600.909+105%0.331+461%0.651+186%3.168-41%
Pe Ratio-1.737+23%-2.244-1.118-50%-0.531-76%-1.219-46%-1.363-39%
Price Per Share3.210-29%4.1452.249+84%1.058+292%1.893+119%2.317+79%
Price To Free Cash Flow Ratio-2.086+23%-2.694-1.430-47%-0.563-79%-1.487-45%-2.359-12%
Price To Total Gains Ratio-7.300+23%-9.426-2.629-72%-2.366-75%4.840-295%-11.314+20%
Quick Ratio--5.6307.764-27%8.968-37%6.724-16%9.202-39%
Return On Assets---0.171-0.215+26%-0.162-5%-0.235+37%-0.301+76%
Return On Equity---0.207-0.501+142%-0.187-10%-0.316+53%-0.319+54%
Total Gains Per Share---0.440-0.018-96%-0.479+9%0.097-555%0.039-1228%
Usd Book Value--60141000.00061133750.000-2%77703500.000-23%52486550.000+15%36061375.000+67%
Usd Book Value Change Per Share---0.440-0.018-96%-0.479+9%0.094-570%0.037-1276%
Usd Book Value Per Share--2.2292.322-4%3.035-27%2.037+9%1.402+59%
Usd Dividend Per Share----0%-0%0.003-100%0.002-100%
Usd Eps---0.462-0.782+69%-0.533+15%-0.481+4%-0.421-9%
Usd Free Cash Flow---10380000.000-10938250.000+5%-12261000.000+18%-9053500.000-13%-7301750.000-30%
Usd Free Cash Flow Per Share---0.385-0.417+8%-0.479+25%-0.352-9%-0.284-26%
Usd Free Cash Flow To Equity Per Share--3.3480.516+549%-0.483+114%0.030+10895%0.077+4268%
Usd Market Cap82176321.000-36%111861869.39059484131.888+88%27072105.750+313%48850570.728+129%59497422.364+88%
Usd Price Per Share3.210-29%4.1452.249+84%1.058+292%1.893+119%2.317+79%
Usd Profit---12465000.000-20137750.000+62%-13975250.000+12%-11368500.000-9%-8810525.000-29%
Usd Revenue--634000.000158500.000+300%-+100%181700.000+249%90850.000+598%
Usd Total Gains Per Share---0.440-0.018-96%-0.479+9%0.097-555%0.039-1228%
 EOD+3 -5MRQTTM+19 -15YOY+19 -155Y+18 -1810Y+18 -18

4.2. Fundamental Score

Let's check the fundamental score of Leap Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.737
Price to Book Ratio (EOD)Between0-11.440
Net Profit Margin (MRQ)Greater than0-19.661
Operating Margin (MRQ)Greater than0-23.375
Quick Ratio (MRQ)Greater than15.630
Current Ratio (MRQ)Greater than15.645
Debt to Asset Ratio (MRQ)Less than10.174
Debt to Equity Ratio (MRQ)Less than10.211
Return on Equity (MRQ)Greater than0.15-0.207
Return on Assets (MRQ)Greater than0.05-0.171
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Leap Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.086
Ma 20Greater thanMa 502.831
Ma 50Greater thanMa 1002.768
Ma 100Greater thanMa 2002.998
OpenGreater thanClose2.860
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -101-3-104-2-106-1-107631524



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets72,825
Total Liabilities12,684
Total Stockholder Equity60,141
 As reported
Total Liabilities 12,684
Total Stockholder Equity+ 60,141
Total Assets = 72,825

Assets

Total Assets72,825
Total Current Assets71,597
Long-term Assets1,228
Total Current Assets
Cash And Cash Equivalents 70,643
Net Receivables 771
Other Current Assets 183
Total Current Assets  (as reported)71,597
Total Current Assets  (calculated)71,597
+/-0
Long-term Assets
Property Plant Equipment 262
Long-term Assets Other 966
Long-term Assets  (as reported)1,228
Long-term Assets  (calculated)1,228
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,684
Long-term Liabilities0
Total Stockholder Equity60,141
Total Current Liabilities
Short-term Debt 262
Accounts payable 6,465
Other Current Liabilities 5,957
Total Current Liabilities  (as reported)12,684
Total Current Liabilities  (calculated)12,684
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock26
Retained Earnings -399,582
Accumulated Other Comprehensive Income 106
Other Stockholders Equity 459,591
Total Stockholder Equity (as reported)60,141
Total Stockholder Equity (calculated)60,141
+/-0
Other
Capital Stock26
Cash and Short Term Investments 70,643
Common Stock Shares Outstanding 26,987
Liabilities and Stockholders Equity 72,825
Net Debt -70,381
Net Invested Capital 60,141
Net Working Capital 58,913
Property Plant and Equipment Gross 483
Short Long Term Debt Total 262



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
15,616
0
0
20,738
18,218
14,722
55,356
48,699
42,717
36,720
31,433
28,149
0
25,624
2,733
6,457
28,779
22,726
17,579
29,062
38,686
34,407
27,126
19,074
19,074
20,137
14,141
7,448
28,742
67,673
60,544
54,371
45,807
37,940
128,080
117,911
105,901
94,203
82,165
70,353
106,547
95,857
83,046
72,825
72,82583,04695,857106,54770,35382,16594,203105,901117,911128,08037,94045,80754,37160,54467,67328,7427,44814,14120,13719,07419,07427,12634,40738,68629,06217,57922,72628,7796,4572,73325,624028,14931,43336,72042,71748,69955,35614,72218,21820,7380015,616
   > Total Current Assets 
14,069
0
0
19,564
17,138
13,781
54,460
46,717
42,141
36,256
30,788
27,917
0
25,621
0
4,029
27,286
20,723
16,501
27,658
36,663
32,048
24,377
17,322
17,322
16,794
11,020
4,241
25,984
65,280
58,401
52,274
43,779
36,020
125,101
116,874
104,944
92,441
79,938
67,950
104,699
93,880
81,761
71,597
71,59781,76193,880104,69967,95079,93892,441104,944116,874125,10136,02043,77952,27458,40165,28025,9844,24111,02016,79417,32217,32224,37732,04836,66327,65816,50120,72327,2864,029025,621027,91730,78836,25642,14146,71754,46013,78117,13819,5640014,069
       Cash And Cash Equivalents 
13,516
0
0
18,995
15,981
11,191
53,285
10,868
41,661
9,588
11,515
20,966
0
25,463
965
793
23,800
17,171
14,203
25,737
35,376
30,481
23,249
16,284
16,284
15,747
10,058
3,891
25,465
64,887
57,975
52,071
43,491
35,734
124,771
114,916
103,220
90,883
78,308
65,500
102,038
91,415
80,743
70,643
70,64380,74391,415102,03865,50078,30890,883103,220114,916124,77135,73443,49152,07157,97564,88725,4653,89110,05815,74716,28416,28423,24930,48135,37625,73714,20317,17123,80079396525,463020,96611,5159,58841,66110,86853,28511,19115,98118,9950013,516
       Short-term Investments 
0
0
0
0
0
0
0
35,313
0
26,324
18,769
6,607
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000006,60718,76926,324035,3130000000
       Net Receivables 
553
0
0
221
1,157
2,590
1,175
379
480
344
504
238
0
158
0
3,170
3,221
3,170
1,894
1,744
998
959
937
836
836
836
752
185
247
181
209
73
22
22
59
1,189
1,233
1,130
1,256
2,099
2,071
2,046
753
771
7717532,0462,0712,0991,2561,1301,2331,189592222732091812471857528368368369379599981,7441,8943,1703,2213,170015802385043444803791,1752,5901,15722100553
       Other Current Assets 
0
0
0
348
0
0
0
157
0
0
0
106
0
0
49
36
116
382
404
177
289
608
191
1,038
202
211
210
165
272
212
217
130
266
264
271
769
491
428
374
351
590
419
265
183
1832654195903513744284917692712642661302172122721652102112021,038191608289177404382116364900106000157000348000
   > Long-term Assets 
1,547
0
0
1,174
1,080
941
896
1,982
576
464
645
232
0
3
0
2,428
1,493
2,003
1,078
1,404
2,023
2,359
2,749
1,752
1,752
3,343
3,121
3,207
2,758
2,393
2,143
2,097
2,028
1,920
2,979
1,037
957
1,762
2,227
2,403
1,848
1,977
1,285
1,228
1,2281,2851,9771,8482,4032,2271,7629571,0372,9791,9202,0282,0972,1432,3932,7583,2073,1213,3431,7521,7522,7492,3592,0231,4041,0782,0031,4932,4280302326454645761,9828969411,0801,174001,547
       Property Plant Equipment 
285
0
0
330
376
379
473
451
432
459
640
232
0
3
119
119
159
160
148
135
123
111
98
86
86
1,559
1,363
1,150
949
792
693
593
489
387
354
495
387
891
791
689
585
480
372
262
2623724805856897918913874953543874895936937929491,1501,3631,5598686981111231351481601591191193023264045943245147337937633000285
       Intangible Assets 
1,240
0
0
827
689
551
413
276
138
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000138276413551689827001,240
       Other Assets 
22
0
0
0
15
0
0
829
0
0
0
766
0
0
1,464
2,309
1,334
1,843
930
1,269
1,900
2,248
2,651
1,666
1,645
1,784
1,758
2,057
1,809
1,601
1,450
2,032
1,469
1,533
2,625
542
570
871
1,436
1,714
1,263
1,497
0
0
001,4971,2631,7141,4368715705422,6251,5331,4692,0321,4501,6011,8092,0571,7581,7841,6451,6662,6512,2481,9001,2699301,8431,3342,3091,46400766000829001500022
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
158
157
151
147
124
126
124
120
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001201241261241471511571580000000000000000000
> Total Liabilities 
4,406
0
0
1,971
2,746
3,195
1,971
2,488
2,821
2,810
2,739
1,279
0
577
27,177
6,457
4,612
4,375
5,994
17,945
22,558
22,272
20,498
9,899
9,899
9,198
8,579
9,197
10,778
7,940
7,406
7,720
7,428
8,056
11,261
10,024
7,344
10,885
12,092
11,487
78,218
11,800
11,038
12,684
12,68411,03811,80078,21811,48712,09210,8857,34410,02411,2618,0567,4287,7207,4067,94010,7789,1978,5799,1989,8999,89920,49822,27222,55817,9455,9944,3754,6126,45727,17757701,2792,7392,8102,8212,4881,9713,1952,7461,971004,406
   > Total Current Liabilities 
1,662
0
0
1,971
2,746
3,195
1,971
2,488
2,821
2,810
2,739
1,279
0
577
27,177
36,157
4,612
4,375
5,994
6,083
5,845
6,027
6,046
6,451
6,451
8,456
7,931
8,486
9,199
6,836
6,715
7,372
7,392
8,056
11,261
9,987
7,344
10,411
11,723
11,225
10,311
11,762
11,038
12,684
12,68411,03811,76210,31111,22511,72310,4117,3449,98711,2618,0567,3927,3726,7156,8369,1998,4867,9318,4566,4516,4516,0466,0275,8456,0835,9944,3754,61236,15727,17757701,2792,7392,8102,8212,4881,9713,1952,7461,971001,662
       Short-term Debt 
0
0
0
0
0
0
0
3,144
0
0
0
3,141
0
0
0
30,274
0
0
0
0
0
0
0
0
738
657
566
474
379
388
398
408
418
354
323
432
363
395
405
416
425
436
369
262
2623694364254164053953634323233544184083983883794745666577380000000030,2740003,1410003,1440000000
       Short Long Term Debt 
0
0
0
0
0
0
0
3,144
0
0
0
3,141
0
0
0
30,274
0
0
0
0
0
0
0
0
738
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000007380000000030,2740003,1410003,1440000000
       Accounts payable 
1,662
0
0
1,095
2,746
0
0
61
0
0
0
394
0
0
2,514
3,225
2,793
3,088
2,598
2,622
4,130
4,766
4,149
6,451
3,579
5,325
4,889
4,571
4,933
2,716
2,547
2,717
3,514
4,343
7,966
4,189
4,287
7,553
6,276
5,657
5,498
6,500
5,899
6,465
6,4655,8996,5005,4985,6576,2767,5534,2874,1897,9664,3433,5142,7172,5472,7164,9334,5714,8895,3253,5796,4514,1494,7664,1302,6222,5983,0882,7933,2252,5140039400061002,7461,095001,662
       Other Current Liabilities 
1,662
0
0
876
2,746
3,195
1,971
2,427
2,821
2,810
2,739
885
0
577
1,900
2,658
1,819
1,287
3,396
3,461
1,715
1,261
1,897
0
2,872
2,474
159
3,441
2,387
2,232
2,270
2,747
2,335
2,609
2,597
5,366
2,694
2,463
5,042
5,152
4,388
4,826
4,770
5,957
5,9574,7704,8264,3885,1525,0422,4632,6945,3662,5972,6092,3352,7472,2702,2322,3873,4411592,4742,87201,8971,2611,7153,4613,3961,2871,8192,6581,90057708852,7392,8102,8212,4271,9713,1952,746876001,662
   > Long-term Liabilities 
2,744
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,531
0
0
0
11,862
16,713
16,245
14,452
3,448
3,448
742
648
711
1,579
1,104
691
348
36
0
0
37
4,650
474
369
262
67,907
38
0
0
003867,9072623694744,6503700363486911,1041,5797116487423,4483,44814,45216,24516,71311,86200070,531000000000000002,744
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
158
157
151
147
124
126
124
120
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001201241261241471511571580000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,715
0
0
0
00067,7150000000000000000000000000000000000000000
       Other Liabilities 
2,744
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,862
16,713
16,245
14,452
3,448
0
0
0
159
1,125
750
441
204
0
0
0
0
0
0
0
0
40
0
0
0
00040000000002044417501,1251590003,44814,45216,24516,71311,8620000000000000000002,744
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,402
0
0
0
0
0
0
162
162
175
181
387
831
623
413
379
345
311
68
34
0
0
0
0
576
0
0
0
0
0000576000034683113453794136238313871811751621620000001,402000000000000000
> Total Stockholder Equity
11,210
0
0
18,767
15,472
11,527
53,385
46,211
39,896
33,910
28,694
26,870
0
25,047
0
-100,231
24,167
18,351
11,585
11,117
16,128
12,135
6,628
9,175
9,175
10,939
5,562
-1,749
17,964
59,733
53,138
46,651
38,379
29,884
116,819
107,887
98,557
83,318
70,073
58,866
28,329
84,057
72,008
60,141
60,14172,00884,05728,32958,86670,07383,31898,557107,887116,81929,88438,37946,65153,13859,73317,964-1,7495,56210,9399,1759,1756,62812,13516,12811,11711,58518,35124,167-100,231025,047026,87028,69433,91039,89646,21153,38511,52715,47218,7670011,210
   Common Stock
20
0
0
20
20
20
46
45
45
46
46
47
0
49
0
0
9
9
9
12
15
15
15
15
15
23
24
24
36
60
60
60
60
60
88
88
88
88
99
99
119
26
26
26
262626119999988888888606060606036242423151515151512999004904746464545462020200020
   Retained Earnings Total Equity00-373,421-360,03100-290,972-273,948-263,572-252,784-241,645-232,119-222,985-216,275-209,218-202,702-195,168-187,172-179,237-170,871-153,535-155,015-148,383-141,019-130,397-123,804-116,989-110,0840000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
5,117
5,156
5,206
5,752
-533
6,755
7,443
8,027
-498
0
0
0
294
-105
331
-269
-268
-158
-19
160
-122
302
322
327
76
988
121
-87
-579
-564
-449
-246
-267
-425
94
690
128
355
414
760
106
10676041435512869094-425-267-246-449-564-579-8712198876327322302-122160-19-158-268-269331-105294000-4988,0277,4436,755-5335,7525,2065,1565,117000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134,347
135,000
135,649
141,770
157,290
160,522
161,468
162,393
187,635
189,831
192,383
193,319
219,642
268,770
269,440
270,155
271,002
271,918
369,761
371,638
372,842
374,108
0
0
387,886
457,038
0
0
00457,038387,88600374,108372,842371,638369,761271,918271,002270,155269,440268,770219,642193,319192,383189,831187,635162,393161,468160,522157,290141,770135,649135,000134,3470000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
11,190
0
0
56,377
56,440
56,855
108,197
114,897
108,197
108,196
108,225
116,622
0
116,424
0
145
105,568
112,274
118,070
141,770
118,604
160,522
161,468
302
162,393
189,831
192,383
193,319
219,642
268,770
269,440
270,155
271,002
271,918
369,761
371,638
372,842
374,108
375,350
376,807
387,846
457,038
458,339
459,591
459,591458,339457,038387,846376,807375,350374,108372,842371,638369,761271,918271,002270,155269,440268,770219,642193,319192,383189,831162,393302161,468160,522118,604141,770118,070112,274105,5681450116,4240116,622108,225108,196108,197114,897108,19756,85556,44056,3770011,190



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-427
Gross Profit-427-427
 
Operating Income (+$)
Gross Profit-427
Operating Expense-86,614
Operating Income-87,041-87,041
 
Operating Expense (+$)
Research Development73,234
Selling General Administrative13,807
Selling And Marketing Expenses427
Operating Expense86,61487,468
 
Net Interest Income (+$)
Interest Income3,610
Interest Expense-5
Other Finance Cost-0
Net Interest Income3,605
 
Pretax Income (+$)
Operating Income-87,041
Net Interest Income3,605
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-81,414-92,668
EBIT - interestExpense = -87,046
-81,414
-81,409
Interest Expense5
Earnings Before Interest and Taxes (EBIT)-87,041-81,409
Earnings Before Interest and Taxes (EBITDA)-86,614
 
After tax Income (+$)
Income Before Tax-81,414
Tax Provision-0
Net Income From Continuing Ops-81,051-81,414
Net Income-81,414
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses87,041
Total Other Income/Expenses Net5,627-3,605
 

Technical Analysis of Leap Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Leap Therapeutics Inc. The general trend of Leap Therapeutics Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Leap Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Leap Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.63 < 3.71 < 4.39.

The bearish price targets are: 2.9799 > 2.42 > 2.125.

Tweet this
Leap Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Leap Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Leap Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Leap Therapeutics Inc. The current macd is 0.10704665.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Leap Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Leap Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Leap Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Leap Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLeap Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Leap Therapeutics Inc. The current adx is 32.46.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Leap Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Leap Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Leap Therapeutics Inc. The current sar is 4.3576.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Leap Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Leap Therapeutics Inc. The current rsi is 59.09. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Leap Therapeutics Inc Daily Relative Strength Index (RSI) ChartLeap Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Leap Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Leap Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Leap Therapeutics Inc Daily Stochastic Oscillator ChartLeap Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Leap Therapeutics Inc. The current cci is 63.88.

Leap Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLeap Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Leap Therapeutics Inc. The current cmo is 23.06.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Leap Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLeap Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Leap Therapeutics Inc. The current willr is -59.89847716.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Leap Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Leap Therapeutics Inc Daily Williams %R ChartLeap Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Leap Therapeutics Inc.

Leap Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Leap Therapeutics Inc. The current atr is 0.3665034.

Leap Therapeutics Inc Daily Average True Range (ATR) ChartLeap Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Leap Therapeutics Inc. The current obv is -2,831,022.

Leap Therapeutics Inc Daily On-Balance Volume (OBV) ChartLeap Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Leap Therapeutics Inc. The current mfi is 78.30.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Leap Therapeutics Inc Daily Money Flow Index (MFI) ChartLeap Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Leap Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Leap Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Leap Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.086
Ma 20Greater thanMa 502.831
Ma 50Greater thanMa 1002.768
Ma 100Greater thanMa 2002.998
OpenGreater thanClose2.860
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Leap Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Leap Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Leap Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Leap Therapeutics Inc

I send you an email if I find something interesting about Leap Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Leap Therapeutics Inc.

Receive notifications about Leap Therapeutics Inc in your mailbox!